AXL Inhibitor BGB324

Known as: BGB324 
An orally available and selective inhibitor of the AXL receptor tyrosine kinase (UFO), with potential antineoplastic activity. Upon administration… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
024620132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Purpose: BCR-ABL kinase inhibitors are employed successfully for chronic myeloid leukemia (CML) treatment. However, resistant… (More)
Is this relevant?
2017
2017
Long non-coding RNA HOTAIR was regarded as an oncogene in multiple cancers. Previous studies have shown that HOTAIR is involved… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
Reactive oxygen species (ROS) can promote or inhibit tumorigenesis. In mesothelioma, asbestos exposure to serous membranes… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have a 5-year survival rate of… (More)
Is this relevant?
2015
2015
Glioblastoma multiforme (GBM) often features a combination of tumour suppressor gene inactivation and multiple oncogene… (More)
Is this relevant?
2015
2015
BACKGROUND & AIMS Liver fibrosis, an important health concern associated to chronic liver injury that provides a permissive… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Novel treatment options in acute myeloid leukemia (AML) are urgently needed; treatment has not changed significantly over the… (More)
Is this relevant?
2015
2015
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related deaths in the United States, and is… (More)
Is this relevant?
2014
2014
New targets for Ewing sarcoma (ES) patients are urgently needed. Therefore, we investigated the expression and genetic… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?